Alnylam Pharmaceuticals
ALNY
#586
Rank
NZ$60.61 B
Marketcap
$469.96
Share price
0.58%
Change (1 day)
56.34%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.55

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$7.25. In 2022 the company made an earnings per share (EPS) of -$16.38 a decrease over its 2021 EPS that were of -$12.70.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.55-59.99%
2022-$16.3829.03%
2021-$12.70-3.36%
2020-$13.14-8.48%
2019-$14.357.67%
2018-$13.3339.74%
2017-$9.5412.94%
2016-$8.4538.84%
2015-$6.08-32.88%
2014-$9.06259.44%
2013-$2.52-31.25%
2012-$3.6752.94%
2011-$2.4030.77%
2010-$1.83-8.77%
2009-$2.0178.13%
2008-$1.13-70.78%
2007-$3.8699.09%
2006-$1.94-43.88%
2005-$3.46-82.33%
2004-$19.56-59.23%
2003-$47.98

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$3.00-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$65.87-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.81 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.48-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.98-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.59-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.61-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.53-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel